IE
URGN icon

Israel Englander’s UroGen Pharma URGN Stock Holding History

Israel Englander’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-45,000
Closed -$898K – 6482
2025
Q3 		$898K Buy
45,000
+100
+0.2% +$1.8K ﹤0.01% 4700
2025
Q2 		$615K Buy
+44,900
New +$431K ﹤0.01% 4759

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Israel Englander's URGN Position: Q2 2026 in Review

Israel Englander reduced its UroGen Pharma (URGN) stake by 71% in Q2 2026, selling an estimated $7.16M and leaving 106,692 shares worth $3.93M. The position accounts for ﹤0.01% of the portfolio, ranked #3232.

Israel Englander first reported a position in URGN in Q4 2017 and has held it in 33 quarters since. The position peaked at $29.3M in Q3 2025. 188 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Israel Englander held 106,692 shares of UroGen Pharma worth $3.93M as of Q2 2026.
  • Israel Englander sold 264,206 UroGen Pharma shares in Q2 2026, an estimated $7.16M.
  • UroGen Pharma made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3232 holding.
  • Israel Englander first reported a position in UroGen Pharma in Q4 2017 and has held it in 33 quarters since.
  • Israel Englander's UroGen Pharma position peaked at $29.3M in Q3 2025.
  • 188 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.